# Multi-omics analysis indicates an association between TAPBP and prostate cancer

**Authors:** Xinlong Wang, Aimin Jiang, Chao Li, Zhiyong Liu, Sarah Jose, Yang Shi, Yang Shi, Yang Shi

PMC · DOI: 10.1371/journal.pone.0336438 · PLOS One · 2025-11-21

## TL;DR

This study identifies TAPBP as a gene strongly associated with prostate cancer through multi-omics analysis.

## Contribution

The study introduces TAPBP as a novel gene strongly linked to prostate cancer using integrated multi-omics approaches.

## Key findings

- Eight genes were found to have protein abundance associated with prostate cancer.
- TAPBP was identified as the most strongly associated gene through combined single-cell and MR analyses.
- Four of the eight genes were validated at the transcriptome level.

## Abstract

Prostate cancer is one of the most common malignant tumors among men worldwide, and surgery remains its mainstay of treatment. It is unclear how prostate cancer develops and what the most effective drug targets are for treating prostate cancer. Therefore, we sought to identify the genes responsible for prostate cancer. By integrating multidimensional and high-throughput data, proteome wide association studies (PWAS), transcriptome wide association studies (TWAS), single-cell sequencing, functional enrichment, Mendelian randomization (MR), and Bayesian co-localization analyses were used to screen for candidate genes that may contribute to prostate cancer and associate with clinical results of prostate cancer. Our comprehensive analysis showed that protein abundance of eight genes was associated with prostate cancer, four of which were validated at the transcriptome level. These 8 candidate genes (MSMB, PLG, CHMP2B, ATF6B, EGF, TAPBP, GAS1 and MMP7) were validated. After combining single-cell sequencing, Mendelian randomization, and Bayesian co-localization analyses, we identified 1 gene (TAPBP) that is strongly associated with prostate cancer.

## Linked entities

- **Genes:** TAPBP (TAP binding protein) [NCBI Gene 6892], MSMB (microseminoprotein beta) [NCBI Gene 4477], PLG (plasminogen) [NCBI Gene 5340], CHMP2B (charged multivesicular body protein 2B) [NCBI Gene 25978], ATF6B (activating transcription factor 6 beta) [NCBI Gene 1388], EGF (epidermal growth factor) [NCBI Gene 1950], GAS1 (growth arrest specific 1) [NCBI Gene 2619], MMP7 (matrix metallopeptidase 7) [NCBI Gene 4316]
- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** ATF6B (activating transcription factor 6 beta) [NCBI Gene 1388] {aka ATF6beta, CREB-RP, CREBL1, G13}, MMP7 (matrix metallopeptidase 7) [NCBI Gene 4316] {aka MMP-7, MPSL1, PUMP-1}, GAS1 (growth arrest specific 1) [NCBI Gene 2619], CHMP2B (charged multivesicular body protein 2B) [NCBI Gene 25978] {aka ALS17, CHMP2.5, DMT1, FTDALS7, VPS2-2, VPS2B}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, MSMB (microseminoprotein beta) [NCBI Gene 4477] {aka HPC13, IGBF, MSP, MSPB, PN44, PRPS}, PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}, TAPBP (TAP binding protein) [NCBI Gene 6892] {aka MHC1D3, NGS17, TAPA, TPN, TPSN}
- **Diseases:** malignant tumors (MESH:D009369), Prostate cancer (MESH:D011471)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12637951/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12637951/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12637951/full.md

---
Source: https://tomesphere.com/paper/PMC12637951